Original Research
Published on 11 Dec 2025
Disproportionality analysis of safety signals for milnacipran and levomilnacipran: a pharmacovigilance study using the FDA adverse event reporting system
in Pharmacoepidemiology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1719881
- 1,391 views
